中文

Chinese Journal of Nature >

2023 , Vol. 45 >Issue 6: 434 - 442

DOI: https://doi.org/10.3969/j.issn.0253-9608.2023.06.008

Progress

Research progress in targeted degradation of membrane proteins

Expand
  • ① School of pharmaceutical sciences, Guizhou University, Guiyang 550025, China; ② Shenzhen Bay Laboratory, Shenzhen 518000, Guangdong Province, China; ③ State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Guizhou University, Guiyang 550025, China

Received date: 2022-12-30

  Online published: 2023-12-21

Fold

Abstract

Membrane proteins are the major participants in cell-cell interactions, and play important roles in many essential cellular processes, such as signal transduction, differentiation, proliferation, and stress response. Traditional small molecule inhibitors and antibodies can play a role by inhibiting and blocking the interactions between membrane proteins and their ligands, but there are often problems of incomplete inhibition or induction of drug resistance. The emerging protein targeted degradation technologies provide a new area for drug discovery. The function of protein is completely lost by specifically degrading in lysosome or proteasome, which expands significantly the drugable scope. This review briefly discusses research progress about targeted membrane protein degradation technologies and presents the promising application of these technologies in clinic.

Cite this article

ZHAO Su, ZHANG Heng, LI Yan, WANG Zhenchao . Research progress in targeted degradation of membrane proteins[J]. Chinese Journal of Nature, 2023 , 45(6) : 434 -442 . DOI: 10.3969/j.issn.0253-9608.2023.06.008

References

[1] UHLÉN M, FAGERBERG L, HALLSTRÖM B M, et al. Tissue-based map of the human proteome [J]. Science, 2015, 347(6220): 1260419.
[2] YANG X, ZHANG X, FU M L, et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses [J]. Cancer Cell, 2014, 25(1): 37-48.
[3] DONG H, STROME S E, SALOMAO D R, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune
evasion [J]. Nat Med, 2002, 8(8): 793-800.
[4] MCDERMOTT L A, WEIR G A, THEMISTOCLEOUS A C, et al. Defining the functional role of NaV1.7 in human nociception [J].
Neuron, 2019, 101(5): 905-919.
[5] WEN T, WANG J, SHI Y, et al. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances [J]. Leukemia, 2021, 35(2): 312-332.
[6] WEINER G J. Building better monoclonal antibody-based therapeutics [J]. Nat Rev Cancer, 2015, 15(6): 361-370.
[7] YANG X, XIE S, YANG X, et al. Opportunities and challenges for antibodies against intracellular antigens [J]. Theranostics, 2019,
9(25): 7792-7806.
[8] CAO C, HE M, WANG L, et al. Chemistries of bifunctional PROTAC degraders [J]. Chem Soc Rev, 2022, 51(16): 7066-7114.

[9] BONDESON D P, MARES A, SMITH I E, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs [J]. Nat Chem

Biol, 2015, 11(8): 611-617.
[10] MULLARD A. Targeted protein degraders crowd into the clinic [J]. Nat Rev Drug Discov, 2021, 20(4): 247-250.
[11] BANIK S M, PEDRAM K, WISNOVSKY S, et al. Lysosometargeting chimaeras for degradation of extracellular proteins [J]. Nature, 2020, 584(7820): 291-297.
[12] COTTON A D, NGUYEN D P, GRAMESPACHER J A, et al. Development of antibody-based PROTACs for the degradation of
the cell-surface immune checkpoint protein PD-L1 [J]. J Am Chem Soc, 2021, 143(2): 593-598.
[13] ZHANG H, HAN Y, YANG Y, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation [J]. J
Am Chem Soc, 2021, 143(40): 16377-16382.
[14] PANCE K, GRAMESPACHER J A, BYRNES J R, et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins [J]. Nat Biotechnol, 2023, 41(2): 273-281.
[15] SAKAMOTO K M, KIM K B, KUMAGAI A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation [J]. Proc Natl Acad Sci USA, 2001, 98(15): 8554-8559.
[16] ZHANG C, HAN X R, YANG X, et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK) [J].
Eur J Med Chem, 2018, 151: 304-314.

[17] QU X, LIU H, SONG X, et al. Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through
both proteosome and autophagy/lysosome degradation system [J]. Eur J Med Chem, 2021, 218: 113328.
[18] ALABI S, JAIME F S, YAO Z, et al. Mutant-selective degradation by BRAF-targeting PROTACs [J]. Nat Commun, 2021, 12(1): 920.
[19] DIEHL C J, CIULLI A. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders [J]. Chem Soc Rev, 2022, 51(19): 8216-8257.
[20] COUTINHO M F, PRATA M J, ALVES S. A shortcut to the lysosome: the mannose-6-phosphate-independent pathway [J]. Mol
Genet Metab, 2012, 107(3): 257-266.

[21] AHN G, BANIK S M, MILLER C L, et al. LYTACs that engage theasialo glycoprotein receptor for targeted protein degradation [J]. Nat Chem Biol, 2021, 17(9): 937-946.
[22] CAIANIELLO D F, ZHANG M, RAY J D, et al. Bifunctional small molecules that mediate the degradation of extracellular proteins [J].
Nat Chem Biol, 2021, 17(9): 947-953.
[23] MAREI H, TSAI W T K, KEE Y S, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation [J]. Nature, 2022,
610(7930): 182-189.
[24] JANSSENS R, STRUYF S, PROOST P. The unique structural and functional features of CXCL12 [J]. Cell Mol Immunol, 2018, 15(4):
299-311.
[25] CHIN J W. Expanding and reprogramming the genetic code [J]. Nature, 2017, 550(7674): 53-60.
[26] UHLÉN M, FAGERBERG L, HALLSTRÖM B M, et al. Tissuebased map of the human proteome [J]. Science, 2015, 347(6220):
1260419.
[27] CHAMBERLAIN P P, HAMANN L G. Development of targeted protein degradation therapeutics [J]. Nat Chem Biol, 2019, 15(10): 937-944.

Options
Outlines

/

〈 〉